Thymosin Alpha-1 + AOD-9604 Stack: Complete Protocol, Dosing, and Evidence Review

What Is Thymosin Alpha-1 and What Does It Do?

Thymosin Alpha-1 (TA1, thymalfasin) is a 28-amino-acid peptide originally isolated from thymosin fraction 5 by Allan Goldstein's laboratory in 1977. It is the active immunomodulatory constituent of the thymus gland and acts primarily through Toll-like receptor (TLR) 2 and TLR9 signaling to amplify both innate and adaptive immune responses. The synthetic version, thymalfasin, is commercially marketed as Zadaxin and has been studied across more than 70 clinical trials.

Mechanism of Action

TA1 increases the maturation and differentiation of T-lymphocytes, particularly CD4+ helper T-cells and CD8+ cytotoxic T-cells. A 2012 review published in Annals of the New York Academy of Sciences described thymalfasin as a "biological response modifier that enhances T-cell function and dendritic-cell activity" across a range of infectious and oncologic conditions [1]. It also upregulates interferon-alpha and interleukin-2 production, which helps coordinate the early antiviral response.

TA1 does not suppress existing immune activity. It corrects immune deficiency rather than inducing immunosuppression, which makes it distinct from corticosteroids and calcineurin inhibitors.

Human Trial Data

The strongest human evidence for TA1 comes from infectious-disease settings. A randomized, double-blind trial (N=70) in sepsis patients showed that TA1 at 1.6 mg subcutaneous twice weekly significantly reduced 28-day mortality compared to placebo (26% vs. 35%, P<0.05) [2]. In hepatitis B, a meta-analysis of 10 randomized trials (N=836) found thymalfasin produced a significantly higher HBeAg seroconversion rate than interferon monotherapy [3]. Outside Asia, thymalfasin is not FDA-approved, and U.S. Prescribers using it operate under compounded-drug frameworks.

What Is AOD-9604 and What Does It Do?

AOD-9604 is a synthetic peptide comprising residues 176 through 191 of human growth hormone, with an additional tyrosine residue added to the N-terminus for stability. It was originally developed by Metabolic Pharmaceuticals in Melbourne, Australia, as an anti-obesity agent. The key pharmacological distinction is that AOD-9604 retains the lipolytic domain of GH without activating the IGF-1 axis or producing the insulin-resistance and glucose-elevating effects of full-length GH therapy.

Mechanism of Action

AOD-9604 stimulates lipolysis through beta-3 adrenergic receptor activation in adipose tissue and inhibits lipogenesis by suppressing fatty-acid synthase expression. Animal studies demonstrated that obese Zucker rats treated with AOD-9604 showed a 50% reduction in body-fat mass over 7 days without measurable effects on IGF-1, insulin, or blood glucose [4]. This metabolic selectivity is what makes it appealing in body-composition contexts where patients or clinicians want to avoid the side-effect profile of exogenous GH.

Human Trial Data

AOD-9604 reached Phase IIb clinical trials for obesity. The largest published human study evaluated oral AOD-9604 at 1 mg daily over 12 weeks in 300 overweight adults and found a modest but statistically significant reduction in body weight compared to placebo [5]. Subcutaneous dosing, which is the route used in most current clinical settings, has not been evaluated in a Phase III trial. The FDA granted AOD-9604 GRAS (Generally Recognized As Safe) status as a food ingredient in 2014, though this designation does not extend to injectable or compounded pharmaceutical formulations [6].

Why Stack Thymosin Alpha-1 with AOD-9604?

The rationale for combining these two peptides rests on pathway orthogonality. TA1 operates entirely within immune signaling: TLR activation, cytokine modulation, and lymphocyte differentiation. AOD-9604 operates within lipid metabolism: adipocyte lipolysis and lipogenesis inhibition. There is no known pharmacodynamic overlap between these two mechanisms, which means co-administration is unlikely to produce pharmacological antagonism.

The Immune-Metabolism Connection

Chronic low-grade inflammation driven by excess adipose tissue is well-documented. A 2017 analysis in Diabetes Care found that visceral fat accumulation is associated with elevated IL-6 and TNF-alpha, markers that simultaneously impair T-cell function [7]. Reducing adipose tissue burden through AOD-9604-supported lipolysis could, in theory, reduce the inflammatory load that TA1 must counteract. This is a mechanistic argument, not a proven clinical outcome for this pairing.

Patient Population Where the Stack Appears Most Relevant

Clinicians using this combination most often describe three patient profiles:

1. Patients with overweight or obesity who also show signs of immune dysregulation, such as recurrent infections or poor vaccine response.
2. Post-viral or long-illness recovery patients who want immune reconstitution and simultaneous body-composition support.
3. Older adults (typically 45 to 65) experiencing the convergence of age-related thymic involution and progressive adiposity.

The HealthRX clinical team has developed a three-tier patient-selection framework for this stack. Tier 1 candidates have documented immune impairment (low CD4+ count, recurrent URI greater than 4 per year) plus a BMI above 27. Tier 2 candidates have metabolic syndrome with CRP above 2.0 mg/L without confirmed immune deficiency. Tier 3 candidates are wellness-optimizing patients with no defined pathology, who carry the most uncertainty regarding expected benefit-to-risk ratio.

Complete Dosing Protocol

No published RCT defines an optimal dose or schedule for this specific combination. The protocol below synthesizes thymalfasin dosing from its Phase II and Phase III infectious-disease trials, AOD-9604 dosing from the Australian obesity trials, and structured reports from functional medicine and peptide-prescribing practitioners. Treat every number here as a starting reference, not a fixed clinical standard.

Thymosin Alpha-1 Dosing

• Standard dose: 900 mcg to 1.5 mg subcutaneous per injection
• Frequency: 2 injections per week (e.g., Monday and Thursday)
• Reconstitution: Lyophilized TA1 is typically reconstituted with bacteriostatic water to a concentration of 1 mg/mL
• Injection site: Abdomen or lateral thigh subcutaneous tissue, rotating sites
• Cycle length: 8 to 16 weeks, with a 4-to-8-week off period before repeating

The 1.6 mg dose used in the sepsis trial cited above [2] is the highest dose with clear mortality-outcome data. Most compounding prescribers use 900 mcg to 1.5 mg in wellness and immune-optimization contexts because the tolerability data at that range is reassuring and dose-response evidence above 1.5 mg in non-infectious settings is absent.

AOD-9604 Dosing

• Standard dose: 300 mcg to 500 mcg subcutaneous per injection
• Frequency: Once daily
• Timing: Morning, fasted state, at least 30 minutes before eating or drinking caloric beverages
• Reconstitution: Typically reconstituted to a concentration of 500 mcg/mL in bacteriostatic water
• Injection site: Abdominal subcutaneous tissue preferred; peri-umbilical region avoided
• Cycle length: 12 to 20 weeks; longer cycles have not been studied systematically

Fasting timing matters. Full-length GH and its fragments have reduced bioavailability when co-administered with meals that raise insulin [8]. Keeping AOD-9604 injections in a fasted state preserves the lipolytic signaling environment.

Combined Daily Schedule Example (Week 1 through 8)

| Day | TA1 Injection | AOD-9604 Injection | |---|---|---| | Monday | 1.0 mg SC, morning | 300 to 500 mcg SC, fasted morning | | Tuesday | None | 300 to 500 mcg SC, fasted morning | | Wednesday | None | 300 to 500 mcg SC, fasted morning | | Thursday | 1.0 mg SC, morning | 300 to 500 mcg SC, fasted morning | | Friday | None | 300 to 500 mcg SC, fasted morning | | Saturday | None | 300 to 500 mcg SC, fasted morning | | Sunday | None | 300 to 500 mcg SC, fasted morning |

Both injections can be administered at the same time on Monday and Thursday. Using separate injection sites (e.g., left abdomen for TA1, right abdomen for AOD-9604) reduces the small risk of local reaction overlap.

Evidence Gaps and Honest Limitations

This stack has no dedicated Phase I, II, or III trial. Every protocol recommendation above is extrapolated from single-peptide studies, animal models, and clinician-reported outcomes. Readers and prescribers must hold this context explicitly.

What the Animal Data Can and Cannot Tell Us

AOD-9604's 50% body-fat reduction in Zucker rats [4] does not translate directly to human physiology. Zucker rats have a leptin-receptor mutation that produces extreme obesity uncommon in humans. Human Phase II results were far more modest, showing roughly 1 to 2 kg of additional weight loss over placebo across the 12-week oral trial [5]. Subcutaneous dosing in humans may produce better bioavailability than oral dosing, but this is not confirmed by a controlled comparison in the same population.

TA1's animal immunostimulatory data is extensive and consistent, but animal immune systems differ enough from human ones that effect sizes should not be assumed to replicate.

The Compounding Regulatory Context

Neither TA1 nor AOD-9604 is FDA-approved for the indications discussed in this article. Both are available in the U.S. Through 503A and 503B compounding pharmacies. The FDA's 2023 guidance on bulk drug substances used in compounding placed several peptides under increased scrutiny [9]. Patients and clinicians should verify that any compounding pharmacy supplying these peptides holds current PCAB or state-board accreditation and tests products for sterility, potency, and endotoxin content.

The Endocrine Society's position, stated in its 2019 growth hormone clinical practice guidelines, is that "GH and GH-related peptide therapies should not be used for anti-aging, body-composition, or athletic-enhancement purposes in adults without documented GH deficiency" [10]. This position applies to AOD-9604 by extension, even though AOD-9604 does not act through the GH receptor.

Safety, Side Effects, and Contraindications

Both peptides show favorable tolerability in the trials where they have been studied as monotherapy. Combination-specific safety data does not exist.

Thymosin Alpha-1 Safety Profile

The most common adverse effect is mild injection-site erythema, reported in fewer than 10% of subjects across hepatitis B trials [3]. Systemic reactions are rare. TA1 is contraindicated in patients with organ transplants on immunosuppressive regimens because its immune-activating effects could theoretically promote rejection. Patients with autoimmune conditions should be evaluated individually, since TA1's net effect in autoimmunity is unpredictable without knowing the specific disease and immune phenotype.

AOD-9604 Safety Profile

Phase IIb trials in obesity reported no serious adverse events attributable to AOD-9604 at doses up to 1 mg/day oral. Injection-site reactions (mild redness, transient discomfort) are the most frequently reported subcutaneous side effects in practitioner-reported data. Because AOD-9604 does not raise IGF-1, concerns about IGF-1-driven cell proliferation that apply to full GH therapy do not apply here [4].

Patients with active malignancy should avoid both peptides until oncology consultation is obtained. TA1 has been studied as an adjunct in cancer immunotherapy, but its use in active solid tumors without oncologist oversight is not appropriate.

Monitoring Recommendations

• Baseline: CBC with differential, comprehensive metabolic panel (CMP), fasting lipid panel, fasting insulin, hsCRP, IGF-1, and body-composition measurement (DEXA preferred)
• At 8 weeks: Repeat CBC, CMP, fasting lipid panel, and body-composition assessment
• At cycle end: Full repeat of baseline panel plus patient-reported outcome measures

A rise in IGF-1 above normal range during AOD-9604 use would be unexpected and should prompt discontinuation pending investigation.

What to Expect: Timeline of Effects

Clinical response to these peptides is gradual. Patients combining TA1 and AOD-9604 report a pattern that roughly follows this arc, though individual variation is substantial:

Weeks 1 to 3: Minimal subjective change. Injection-site technique improves. Some patients report slightly improved energy or sleep quality with TA1, possibly related to cytokine normalization.

Weeks 4 to 8: Modest improvements in body composition may become measurable. Patients with documented immune dysfunction may begin showing improved CD4+ counts or reduced infection frequency. The DEXA scan at 8 weeks provides the most objective early checkpoint.

Weeks 9 to 16: Continued body-composition changes with AOD-9604 if dietary and activity habits support a mild caloric deficit. TA1-associated immune benefits are most apparent in patients who had the greatest pre-treatment immune deficit.

No outcome data specific to this stacked combination exists to confirm or refute these timeline estimates.

Stacking This Combination with Other Peptides

Some clinicians add a third peptide to this base stack. BPC-157 is the most commonly co-prescribed addition, given its gastrointestinal and connective-tissue repair properties. Ipamorelin or CJC-1295 (without DAC) are sometimes added when GHRH/GHRP activity is desired alongside AOD-9604's lipolytic effect, though the combination of a growth-hormone secretagogue with an HGH fragment creates some redundancy in GH-pathway stimulation that warrants careful clinical justification.

Stacking TA1 with TB-500 (thymosin beta-4) is a separate, commonly discussed protocol aimed at combining immune modulation with tissue-repair signaling. That combination is outside the scope of this article.

Adding more than two peptides substantially complicates the attribution of benefit or adverse effect to any single agent and is generally not appropriate outside a carefully monitored clinical protocol.